Novome Biotechnologies

Novome Biotechnologies

Edit info

  • Founded: 2016
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Enteric hyperoxaluria
  • Drug types: NPH, GI, ONC
  • Lead product: NOV-001
  • Funding: $43.5M B Sep 2022; $33M A Jan 2020
  • Investors: Tencent, University of Minnesota, Navian Investments, Colorcon Ventures, Touchdown Ventures, DCVC Bio, 5AM Ventures, Alta Partners, Alexandria Venture Investments


novomebio.com

linkedin.com

job board


Drug notes:

Undisclosed Clin0 IBS; undisclosed programs IBD, immuno-oncology

About:

Novome is engineering activities into the gut microbiome to treat chronic diseases. The gut microbiome performs many activities within the body such as food digestion and immune system regulation. Instead of discovering drugs, Novome’s approach is to build them by designing cell therapies referred to as GEMMs - Genetically Engineered Microbial Medicines. Novome’s proprietary platform is the first to colonize the gut with engineered microbes to deliver precise and controllable activities. Novome has already received promising results of their first product NOV-001 in a Phase I trial in healthy volunteers showing safe colonization. With this, Novome now plans to expand a pipeline of GEMMs for a wide range of diseases.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com